Dennis H. Langer

After graduating from Georgetown School of Medicine and Harvard Law School, Dr. Langer spent over 55 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK and as President at Dr. Reddy's, NA. He was a Director at Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma) and Delcath Systems. Dr. Langer is a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a Clinical Psychiatry Professor at Georgetown and serves on the Dean's Advisory Board of Harvard Law School.